Shares of Incyte Co. (NASDAQ:INCY) have been assigned a consensus rating of “Buy” from the twenty-eight research firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation, seventeen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $143.27.

A number of brokerages have issued reports on INCY. BMO Capital Markets dropped their target price on shares of Incyte from $163.00 to $162.00 and set an “outperform” rating for the company in a report on Thursday, October 26th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Incyte in a research note on Wednesday, October 25th. Goldman Sachs Group initiated coverage on shares of Incyte in a research note on Friday, October 6th. They set a “buy” rating and a $160.00 price objective for the company. Jefferies Group reissued a “buy” rating on shares of Incyte in a research note on Friday, October 6th. Finally, Oppenheimer set a $135.00 price objective on shares of Incyte and gave the stock a “hold” rating in a research note on Tuesday, October 31st.

In related news, Director Paul A. Friedman sold 28,507 shares of Incyte stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $105.24, for a total transaction of $3,000,076.68. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider David W. Gryska sold 3,915 shares of Incyte stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $105.63, for a total transaction of $413,541.45. The disclosure for this sale can be found here. In the last quarter, insiders sold 44,878 shares of company stock worth $4,636,494. 17.70% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC lifted its holdings in shares of Incyte by 13.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 108 shares in the last quarter. Seven Eight Capital LP purchased a new stake in Incyte during the 2nd quarter worth $129,000. Sun Life Financial INC increased its stake in Incyte by 9,069.2% during the 2nd quarter. Sun Life Financial INC now owns 1,192 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 1,179 shares during the period. Private Advisor Group LLC purchased a new stake in Incyte during the 3rd quarter worth $203,000. Finally, Caxton Associates LP purchased a new stake in Incyte during the 3rd quarter worth $257,000. Institutional investors and hedge funds own 90.76% of the company’s stock.

Shares of Incyte (INCY) traded up $1.61 during trading on Friday, reaching $91.92. 2,104,900 shares of the company’s stock were exchanged, compared to its average volume of 1,965,708. Incyte has a 12 month low of $88.81 and a 12 month high of $153.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.81 and a current ratio of 4.82. The stock has a market capitalization of $19,470.00, a PE ratio of -114.90 and a beta of 0.74.

Incyte (NASDAQ:INCY) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.11. Incyte had a negative net margin of 10.90% and a negative return on equity of 12.91%. The company had revenue of $381.50 million during the quarter, compared to analysts’ expectations of $360.34 million. During the same period last year, the company posted $0.19 earnings per share. The firm’s quarterly revenue was up 41.6% compared to the same quarter last year. research analysts predict that Incyte will post -1.35 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Incyte Co. (INCY) Given Consensus Recommendation of “Buy” by Brokerages” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2018/01/19/incyte-co-incy-given-consensus-recommendation-of-buy-by-brokerages.html.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.